Neuronetics Q4 Earnings Call Highlights
View original at finance.yahoo.comNeuronetics Q4 Earnings Call Highlights Neuronetics logo Key Points Board appointed Dan Reuvers as CEO effective March 23, as Neuronetics transitions leadership while continuing its strategy to operate a vertically integrated mental-health company combining NeuroStar technology and Greenbrook clinics…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The company shipped 49 systems in the quarter, with average selling price above its target for a fourth consecutive quarter
60% confidenceThe debt paydown would reduce annual interest expense by close to $600,000
60% confidenceClinic revenue was $23.5 million, representing 37% adjusted pro forma growth, driven by increased treatments across both NeuroStar TMS and Spravato
60% confidenceThe combined company delivered strong fourth quarter results and reached a key milestone of positive operating cash flow in the period
60% confidenceTRICARE West expanded coverage for TMS therapy to include adolescents age 15 and older diagnosed with depression, effective across 26 states
60% confidenceFull-year 2026 operating cash flow is expected to be negative $13 million to negative $17 million, with the highest cash burn in the first quarter and improvement beginning in the second quarter, with positive operating cash flow in the second half
60% confidenceIn the first full year post-acquisition, Neuronetics grew revenue, improved cash generation, and strengthened its platform for supporting both its NeuroStar device business and Greenbrook's clinic-based care delivery network
60% confidenceCompass has about seven strategic collaborations for commercial readiness and Greenbrook is one of them
60% confidenceCompass has about seven strategic collaborations for commercial readiness and Greenbrook is one of them
60% confidenceCompass has completed two phase 3 studies showing highly statistically significant and clinically meaningful results, including durable improvement through at least 26 weeks after one or two doses
60% confidenceThe Spravato rollout is nearly complete, with 84 clinics providing the treatment
60% confidenceThe $5 million principal payment to Perceptive did not come from restricted cash and the debt paydown would reduce annual interest expense by close to $600,000
60% confidenceFirst-quarter 2026 revenue guidance was $33 million to $35 million, with management citing seasonality in both clinic volume and capital sales, as well as weather-related impacts
60% confidenceFourth-quarter total revenue was $41.8 million, up 86% year-over-year, primarily due to the inclusion of Greenbrook operations. On an adjusted pro forma basis, revenue increased 23% versus the prior year
60% confidenceThe fourth-quarter gross margin was the company's highest quarterly margin of the year, citing clinic efficiency efforts and favorable product mix
60% confidenceThe debt paydown would reduce annual interest expense by close to $600,000
60% confidenceThe debt paydown would reduce annual interest expense by close to $600,000
60% confidenceThe Greenbrook network is positioned to offer REMS-compliant therapies and expects only limited incremental investment to support COMP360 if approved, given alignment with existing Spravato operations
60% confidenceFull-year 2026 operating cash flow is expected to be negative $13 million to negative $17 million, with the highest cash burn in the first quarter and improvement beginning in the second quarter, with positive operating cash flow in the second half
60% confidenceThe company's strategy following the Greenbrook acquisition was to build a vertically integrated mental health company combining technology, clinical infrastructure, and scale to expand patient access to treatment
60% confidenceThe debt paydown would reduce annual interest expense by close to $600,000
60% confidenceThe company shipped 49 systems in the quarter, with average selling price above its target for a fourth consecutive quarter
60% confidenceTotal cash was $34.1 million at Dec. 31, 2025, including $28.1 million of cash and cash equivalents and $6.0 million of restricted cash, compared with $19.5 million at year-end 2024
60% confidenceThe clinic business is expected to grow in the double digits to mid-teens for 2026, while the NeuroStar business is expected to grow in the low to mid-single digits
60% confidenceClinic revenue was $23.5 million, representing 37% adjusted pro forma growth, driven by increased treatments across both NeuroStar TMS and Spravato
60% confidenceThe company shipped 49 systems in the quarter, with average selling price above its target for a fourth consecutive quarter
60% confidenceThe Greenbrook network is positioned to offer REMS-compliant therapies and expects only limited incremental investment to support COMP360 if approved, given alignment with existing Spravato operations
60% confidenceClinic revenue was $23.5 million, representing 37% adjusted pro forma growth, driven by increased treatments across both NeuroStar TMS and Spravato
60% confidenceNeuroStar revenue (systems plus treatment sessions) was $18.3 million, representing 9% growth year-over-year on a pro forma basis
60% confidenceCOMP360 would be administered in supervised doses within a clinic setting, without a daily or recurring protocol, and would be administered under a REMS protocol similar to Spravato
60% confidence